RUVBL2: A GPCR Target for Cancer and Neurodegenerative Diseases

Target Name: RUVBL2

NCBI ID: G10856

RUVBL2

RUVBL2: A GPCR Target for Cancer and Neurodegenerative Diseases

RUVBL2 (TIP49B), a protein that belongs to the superfamily of G-protein-coupled receptors (GPCRs), is a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

RUVBL2 is a 19-kDa transmembrane protein that is expressed in various tissues and cells, including the brain, pancreas, and testes. It is characterized by a long N-terminal alkaline amino acid residue, a conserved proline-rich region, and a C-terminal GPCR-specific domain. The GPCR-specific domain is composed of a leucine-rich region (LRR) and a helix-containing region (HCR) that are responsible for the protein's GPCR-specificity.

The RUVBL2 gene is located on chromosome 11q22 and has a gene length of 1381 base pairs. It has been shown to be involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling.

One of the most significant functions of RUVBL2 is its role in neurotransmission. RUVBL2 is a GPCR that is expressed in the brain and is involved in the regulation of neurotransmitter release and uptake. Studies have shown that RUVBL2 is involved in the regulation of dopamine release in response to various stimuli, including pharmacological agents.

In addition to its role in neurotransmission, RUVBL2 is also involved in the regulation of hormone signaling. It has been shown to be involved in the regulation of testosterone levels in male mice and has been identified as a potential drug target for testicular cancer.

Another promising function of RUVBL2 is its role in cancer progression. Studies have shown that RUVBL2 is involved in the regulation of cell survival and has been identified as a potential drug target for various cancers, including breast, ovarian, and colorectal cancers.

In conclusion, RUVBL2 is a protein that is involved in various physiological processes, including neurotransmission, hormone signaling, and cancer progression. Its potential as a drug target makes it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the functions of RUVBL2 and its potential as a drug.

Protein Name: RuvB Like AAA ATPase 2

Functions: Possesses single-stranded DNA-stimulated ATPase and ATP-dependent DNA helicase (5' to 3') activity; hexamerization is thought to be critical for ATP hydrolysis and adjacent subunits in the ring-like structure contribute to the ATPase activity (PubMed:10428817, PubMed:17157868, PubMed:33205750). Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:14966270). This modification may both alter nucleosome -DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription (PubMed:14966270). This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair (PubMed:14966270). The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400 (PubMed:14966270). NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage (PubMed:14966270). Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AZ1 from the nucleosome (PubMed:24463511). Proposed core component of the chromatin remodeling INO80 complex which exhibits DNA- and nucleosome-activated ATPase activity and catalyzes ATP-dependent nucleosome sliding (PubMed:16230350, PubMed:21303910). Plays an essential role in oncogenic transformation by MYC and also modulates transcriptional activation by the LEF1/TCF1-CTNNB1 complex (PubMed:10882073, PubMed:16014379). May also inhibit the transcriptional activity of ATF2 (PubMed:11713276). Involved in the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway where it negatively regulates expression of ER stress response genes (PubMed:25652260). May play a role in regulating the composition of the U5 snRNP complex (PubMed:28561026)

The "RUVBL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RUVBL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets